A Study of Guselkumab in Participants With Active Lupus Nephritis (ORCHID-LN)

First posted May, 2020, Updated August, 2021; Recruiting
CATEGORIES: Lupus Nephritis

The purpose of this Phase 2 study is to evaluate the efficacy of guselkumab in participants with active lupus nephritis (LN).

This study is being offered at 8 LuCIN sites – institutions that are members of the Lupus Clinical Investigators Network managed by Lupus Therapeutics, an affiliate of the Lupus Research Alliance.

To Learn More Contact
Janssen at 844-434-4210 or email JNJ.CT@sylogent.com

ClinicalTrials.gov identifier (NCT number): NCT04376827

Learn More

Sign up for our Newsletter

Use this tool to search all lupus trials and create a personalized list of studies by the type of lupus you have and where you live.

Sign up